SCHEMBL1707792

SCHEMBL1707792

COC(=O)c1cccc(Nc2c(C)cccc2N)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
HSD17B10 Q99714 2/20 0.51
CFTR P13569 1/20 0.51
PTGS2 P35354 2/20 0.47
FFAR4 Q5NUL3 1/20 0.47
LMNA P02545 3/20 0.45
MEN1 O00255 1/20 0.44
AKR1B10 O60218 1/20 0.44
TRPA1 O75762 1/20 0.44
ABCB11 O95342 1/20 0.44
DHFR P00374 1/20 0.44
MPO P05164 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CHRM1 P11229 1/20 0.44
CYP2C9 P11712 1/20 0.44
AKR1B1 P15121 1/20 0.44
PTGS1 P23219 1/20 0.44
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707753 0.84 ALDH1A1 (0.60) ALDH1A1HSD17B10CFTRPTGS2FFAR4
SCHEMBL1707741 0.83 LMNA (0.50) ALDH1A1HSD17B10CFTRPTGS2FFAR4
SCHEMBL15465911 0.82 FFAR4 (0.43) ALDH1A1HSD17B10CFTRPTGS2FFAR4
SCHEMBL16301844 0.78 RAPGEF4 (0.59) ALDH1A1HSD17B10PTGS2LMNAMEN1
SCHEMBL31303445 0.78 ALDH1A1 (0.69) ALDH1A1HSD17B10CFTRFFAR4LMNA
SCHEMBL543352 0.78 ALDH1A1 (0.69) ALDH1A1HSD17B10CFTRFFAR4LMNA
Hydrochloric Acid SCHEMBL6980967 0.77 ALDH1A1 (0.67) ALDH1A1HSD17B10CFTRFFAR4LMNA
SCHEMBL1708210 0.77 FFAR4 (0.52) ALDH1A1HSD17B10CFTRFFAR4LMNA
SCHEMBL6808925 0.77 PTGS2 (0.62) ALDH1A1HSD17B10PTGS2LMNAMEN1
SCHEMBL524457 0.75 LMNA (0.53) ALDH1A1HSD17B10CFTRPTGS2FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
EP-2440541-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-04-18 EP disclosed
WO-2010143733-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF GPR119, INSR, GLP1R ALDH1A1 3930/4885HSD17B10 774/4885CFTR 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.